| 引用本文: | 张冬阳,宋明芬,闫盼,李静,汪程鹏,王晟东,汤剑平,张丽娜,唐文新,盘圣明,夏泳,谭忠林,施剑飞,朱婉儿.氟伏沙明和CYP1A2*1F基因多态性对血清奥氮平浓度的影响[J].中国现代应用药学,2020,37(5):591-594. |
| ZHANG Dongyang,SONG Mingfen,YAN Pan,LI Jing,WANG Chengpeng,WANG Shengdong,TANG Jianping,ZHANG Lina,TANG Wenxin,PAN Shengming,XIA Yong,TAN Zhonglin,SHI Jianfei,ZHU Wan'er.Influences of Fluvoxamine and CYP1A2*1F Genetic Polymorphism on Serum Concentration of Olanzapine[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(5):591-594. |
|
| |
|
|
| 本文已被：浏览 1957次 下载 962次 |
码上扫一扫！ |
|
|
| 氟伏沙明和CYP1A2*1F基因多态性对血清奥氮平浓度的影响 |
|
张冬阳1, 宋明芬2, 闫盼2, 李静2, 汪程鹏1, 王晟东2, 汤剑平1, 张丽娜1, 唐文新1, 盘圣明1, 夏泳1, 谭忠林1, 施剑飞1, 朱婉儿3
|
|
1.杭州市第七人民医院精神科, 杭州 310013;2.杭州市第七人民医院分子生物学实验室, 杭州 310013;3.浙江大学心理健康教育与咨询中心, 杭州 310058)
|
|
| 摘要: |
| 目的 研究氟伏沙明与细胞色素P450酶1A2（cytochrome P450 1A2，CYP1A2）基因*1F位点多态性对精神分裂症患者血清奥氮平浓度的影响。方法 入组精神分裂症患者单用奥氮平者（奥氮平组）92例以及奥氮平联用氟伏沙明者（联合组）103例，采集血液，测定CYP1A2*1F基因型以及血清奥氮平浓度，比较2组以及CYP1A2*1F各个基因型间的血清奥氮平浓度差异。结果 奥氮平组血清奥氮平浓度（3.39±2.70）mg·L-1·mg-1显著低于联合组（5.14±3.06）mg·L-1·mg-1（t=4.23，P=0.000）。AA型血清奥氮平浓度比CC型低[奥氮平组：（2.46±1.64）mg·L-1·mg-1 vs（4.42±2.88）mg·L-1·mg-1，P<0.05；联合组：（4.06±2.65）mg·L-1·mg-1 vs（6.86±3.25）mg·L-1·mg-1，P<0.01]，但是CA型与CC型的差异无统计学显著意义。结论 氟伏沙明可升高血清奥氮平浓度；不同基因型个体，血清奥氮平浓度不同；应根据氟伏沙明使用情况和CYP1A2*1F基因型个体化给药。 |
| 关键词: 精神分裂症 CYP1A2*1F基因多态性 氟伏沙明 血清奥氮平浓度 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.05.015 |
| 分类号:R969.4 |
| 基金项目:浙江省科技厅重大科技专项重大社会发展项目（2015C03054） |
|
| Influences of Fluvoxamine and CYP1A2*1F Genetic Polymorphism on Serum Concentration of Olanzapine |
|
ZHANG Dongyang1, SONG Mingfen2, YAN Pan2, LI Jing2, WANG Chengpeng1, WANG Shengdong2, TANG Jianping1, ZHANG Lina1, TANG Wenxin1, PAN Shengming1, XIA Yong1, TAN Zhonglin1, SHI Jianfei1, ZHU Wan'er3
|
|
1.Hangzhou Seventh People's Hospital, Department of Psychiatry, Hangzhou 310013, China;2.Hangzhou Seventh People's Hospital, Molecular Biological Labratory, Hangzhou 310013, China;3.Mental Health Education and Counseling Center, Zhejiang University, Hangzhou 310058, China
|
| Abstract: |
| OBJECTIVE To study the influences of fluvoxamine and cytochrome P450 1A2*1F(CYP1A2*1F) genetic polymorphism on the serum concentration of olanzapine in schizophrenia patients. METHODS Schizophrenia patients treated with olanzapine alone(the olanzapine group, 92 cases) and olanzapine combined with fluvoxamine(the combined group, 103 cases) were recruited. The blood samples were collected for the determinations of CYP1A2*1F genotypes and serum concentrations of olanzapine. Then the serum concentrations of olanzapine were compared between two groups, as well as among the different CYP1A2*1F genotypes. RESULTS The serum concentration of olanzapine in the olanzapine group (3.39±2.70)mg·L-1·mg-1 was obviously lower than that of the combined group(5.14±3.06)mg·L-1·mg-1(t=4.23, P=0.000). The serum concentration of olanzapine of AA genotype had an obvious decrease as compared with that of CC type [the olanzapine group: (2.46±1.64)mg·L-1·mg-1 vs (4.42±2.88)mg·L-1·mg-1, P<0.05; the combined group: (4.06±2.65)mg·L-1·mg-1 vs (6.86±3.25)mg·L-1·mg-1, P<0.01]. However, the serum concentrations of olanzapine were not significantly different between CA type and CC type. CONCLUSION Fluvoxamine may increase the serum concentration of olanzapine. The serum concentrations of olanzapine are different among CYP1A2*1F genotypes. Individual adminiatration of olazanpine based on the use of fluvoxamine and the genotypes of CYP1A2*1F is needed. |
| Key words: schizophrenia CYP1A2*1F genetic polymorphism fluvoxamine serum concentration of olanzapine |
|
|
|
|
